FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986363025> ?p ?o ?g. }

• W1986363025 endingPage "710" @default.
• W1986363025 startingPage "704" @default.
• W1986363025 abstract "Purpose: Radiotherapy (RT) for patients with glioblastoma improves survival and is recommended for nearly all patients with this diagnosis. However, the response to RT is variable in this patient population. Prior studies have suggested that underlying genetic alterations in the tumor may account for some of this treatment-related heterogeneity. It has been previously reported that epidermal growth factor receptor (EGFR) gene amplification and TP53 mutation correlate with the response to RT in patients with glioblastoma. Methods and Materials: We sought to identify molecular markers that could predict the response to RT, progression-free survival after RT, and overall survival among 75 glioblastoma patients treated with RT at a single institution. Genetic analyses assessed EGFR amplification, TP53 mutations, CDKN2A/p16 deletion, and losses of chromosomes 1p, 10q, and 19q. Results: Unlike previous reports, no association of EGFR amplification with response to RT, progression-free survival, or overall survival was found. Moreover, no association was found between these endpoints and the other genetic alterations assayed (TP53 mutation, CDKN2A/p16 deletion, loss of heterozygosity 1p, loss of heterozygosity 10q, and loss of heterozygosity 19q). However, in accordance with recent observations that the prognostic effects of genetic alterations in glioblastoma may depend on patient age, we observed age-dependent prognostic effects of TP53 and CDKN2A/p16 alterations in our patient population. For patients ≥57 years old, those harboring TP53 mutations had a decreased overall survival compared with patients without TP53 mutations. Similarly, deletion of CDKN2A/p16 in patients ≥57 years was associated with decreased progression-free survival after RT and a trend toward a shorter time to progression after RT compared with similar patients without the deletion. Conclusion: These data contrast with previous studies regarding the significant prognostic effect of EGFR with respect to RT response. Although our observations regarding the age-dependent prognostic effects of TP53 and CDKN2A/p16 are consistent with a prior report regarding these alterations, the present results should be considered preliminary, given the small sample size. Purpose: Radiotherapy (RT) for patients with glioblastoma improves survival and is recommended for nearly all patients with this diagnosis. However, the response to RT is variable in this patient population. Prior studies have suggested that underlying genetic alterations in the tumor may account for some of this treatment-related heterogeneity. It has been previously reported that epidermal growth factor receptor (EGFR) gene amplification and TP53 mutation correlate with the response to RT in patients with glioblastoma. Methods and Materials: We sought to identify molecular markers that could predict the response to RT, progression-free survival after RT, and overall survival among 75 glioblastoma patients treated with RT at a single institution. Genetic analyses assessed EGFR amplification, TP53 mutations, CDKN2A/p16 deletion, and losses of chromosomes 1p, 10q, and 19q. Results: Unlike previous reports, no association of EGFR amplification with response to RT, progression-free survival, or overall survival was found. Moreover, no association was found between these endpoints and the other genetic alterations assayed (TP53 mutation, CDKN2A/p16 deletion, loss of heterozygosity 1p, loss of heterozygosity 10q, and loss of heterozygosity 19q). However, in accordance with recent observations that the prognostic effects of genetic alterations in glioblastoma may depend on patient age, we observed age-dependent prognostic effects of TP53 and CDKN2A/p16 alterations in our patient population. For patients ≥57 years old, those harboring TP53 mutations had a decreased overall survival compared with patients without TP53 mutations. Similarly, deletion of CDKN2A/p16 in patients ≥57 years was associated with decreased progression-free survival after RT and a trend toward a shorter time to progression after RT compared with similar patients without the deletion. Conclusion: These data contrast with previous studies regarding the significant prognostic effect of EGFR with respect to RT response. Although our observations regarding the age-dependent prognostic effects of TP53 and CDKN2A/p16 are consistent with a prior report regarding these alterations, the present results should be considered preliminary, given the small sample size." @default.
• W1986363025 created "2016-06-24" @default.
• W1986363025 creator A5001528733 @default.
• W1986363025 creator A5018044773 @default.
• W1986363025 creator A5021122229 @default.
• W1986363025 creator A5045425111 @default.
• W1986363025 creator A5069527451 @default.
• W1986363025 creator A5083466690 @default.
• W1986363025 date "2005-11-01" @default.
• W1986363025 modified "2023-10-17" @default.
• W1986363025 title "Genetic analyses for predictors of radiation response in glioblastoma" @default.
• W1986363025 cites W115284733 @default.
• W1986363025 cites W1505624690 @default.
• W1986363025 cites W1965454055 @default.
• W1986363025 cites W1972122268 @default.
• W1986363025 cites W1976480037 @default.
• W1986363025 cites W1985724763 @default.
• W1986363025 cites W2001493754 @default.
• W1986363025 cites W2001598945 @default.
• W1986363025 cites W2001660159 @default.
• W1986363025 cites W2009489886 @default.
• W1986363025 cites W2015259742 @default.
• W1986363025 cites W2039866113 @default.
• W1986363025 cites W2068731683 @default.
• W1986363025 cites W2105113857 @default.
• W1986363025 cites W2109029371 @default.
• W1986363025 cites W2109557450 @default.
• W1986363025 cites W2114998237 @default.
• W1986363025 cites W2122961418 @default.
• W1986363025 cites W2143739956 @default.
• W1986363025 cites W2161295719 @default.
• W1986363025 cites W2170665695 @default.
• W1986363025 cites W307329015 @default.
• W1986363025 cites W4231637567 @default.
• W1986363025 cites W54894650 @default.
• W1986363025 cites W88867000 @default.
• W1986363025 doi "https://doi.org/10.1016/j.ijrobp.2005.03.059" @default.
• W1986363025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15978739" @default.
• W1986363025 hasPublicationYear "2005" @default.
• W1986363025 type Work @default.
• W1986363025 sameAs 1986363025 @default.
• W1986363025 citedByCount "22" @default.
• W1986363025 countsByYear W19863630252012 @default.
• W1986363025 countsByYear W19863630252013 @default.
• W1986363025 countsByYear W19863630252015 @default.
• W1986363025 countsByYear W19863630252017 @default.
• W1986363025 countsByYear W19863630252019 @default.
• W1986363025 countsByYear W19863630252020 @default.
• W1986363025 crossrefType "journal-article" @default.
• W1986363025 hasAuthorship W1986363025A5001528733 @default.
• W1986363025 hasAuthorship W1986363025A5018044773 @default.
• W1986363025 hasAuthorship W1986363025A5021122229 @default.
• W1986363025 hasAuthorship W1986363025A5045425111 @default.
• W1986363025 hasAuthorship W1986363025A5069527451 @default.
• W1986363025 hasAuthorship W1986363025A5083466690 @default.
• W1986363025 hasConcept C104317684 @default.
• W1986363025 hasConcept C121608353 @default.
• W1986363025 hasConcept C126322002 @default.
• W1986363025 hasConcept C143589142 @default.
• W1986363025 hasConcept C143998085 @default.
• W1986363025 hasConcept C180754005 @default.
• W1986363025 hasConcept C2776194525 @default.
• W1986363025 hasConcept C2780265364 @default.
• W1986363025 hasConcept C2780739268 @default.
• W1986363025 hasConcept C2908647359 @default.
• W1986363025 hasConcept C3019894029 @default.
• W1986363025 hasConcept C502942594 @default.
• W1986363025 hasConcept C54355233 @default.
• W1986363025 hasConcept C71924100 @default.
• W1986363025 hasConcept C86803240 @default.
• W1986363025 hasConcept C99454951 @default.
• W1986363025 hasConceptScore W1986363025C104317684 @default.
• W1986363025 hasConceptScore W1986363025C121608353 @default.
• W1986363025 hasConceptScore W1986363025C126322002 @default.
• W1986363025 hasConceptScore W1986363025C143589142 @default.
• W1986363025 hasConceptScore W1986363025C143998085 @default.
• W1986363025 hasConceptScore W1986363025C180754005 @default.
• W1986363025 hasConceptScore W1986363025C2776194525 @default.
• W1986363025 hasConceptScore W1986363025C2780265364 @default.
• W1986363025 hasConceptScore W1986363025C2780739268 @default.
• W1986363025 hasConceptScore W1986363025C2908647359 @default.
• W1986363025 hasConceptScore W1986363025C3019894029 @default.
• W1986363025 hasConceptScore W1986363025C502942594 @default.
• W1986363025 hasConceptScore W1986363025C54355233 @default.
• W1986363025 hasConceptScore W1986363025C71924100 @default.
• W1986363025 hasConceptScore W1986363025C86803240 @default.
• W1986363025 hasConceptScore W1986363025C99454951 @default.
• W1986363025 hasIssue "3" @default.
• W1986363025 hasLocation W19863630251 @default.
• W1986363025 hasLocation W19863630252 @default.
• W1986363025 hasOpenAccess W1986363025 @default.
• W1986363025 hasPrimaryLocation W19863630251 @default.
• W1986363025 hasRelatedWork W2001734836 @default.
• W1986363025 hasRelatedWork W2007389278 @default.
• W1986363025 hasRelatedWork W2013129940 @default.
• W1986363025 hasRelatedWork W2045061462 @default.
• W1986363025 hasRelatedWork W2353484916 @default.
• W1986363025 hasRelatedWork W2404120231 @default.

• next